Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • SoleInvictus@lemmy.world
    link
    fedilink
    arrow-up
    10
    arrow-down
    4
    ·
    1 year ago

    Excuse me, that study only examined 140,219 patients. You’ll need WAY more, at least one million, to argue against the anecdotal opinion of a random, unspecified ‘medical professional’.

    /s so hard

    • thepianistfroggollum@lemmynsfw.com
      link
      fedilink
      English
      arrow-up
      2
      arrow-down
      5
      ·
      1 year ago

      Only 2.6% of the sample were given paxlovid, and they didn’t control for vaccination status.

      Also, it only covered 1 month nearly 2 years ago in a single country, and the virus has mutated several times since then.

      • SoleInvictus@lemmy.world
        link
        fedilink
        arrow-up
        2
        ·
        1 year ago

        The best part about having a background in statistics is watching people who don’t understand statistics try to explain why the math that doesn’t support their point actually does, somehow.

      • Muddybulldog@mylemmy.win
        link
        fedilink
        English
        arrow-up
        2
        ·
        1 year ago

        Paxlovid is a 3CL protease inhibitor. It modifies the primary enzyme that is common across all cornavirus.